Allogene Therapeutics (ALLO) Shares Outstanding (2017 - 2026)

Allogene Therapeutics has disclosed Shares Outstanding across 10 years of filings, most recently posting $244.8 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $244.8 million, up 11.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $244.8 million (up 11.99% YoY), and the FY2025 annual result was $229.4 million, up 8.11% from the prior year.
• Shares Outstanding came in at $244.8 million for Q1 2026 at Allogene Therapeutics, up from $229.4 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $244.8 million in Q1 2026 to a low of $143.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $170.5 million (2024), against an average of $186.0 million.
• Across the five-year window, Shares Outstanding plunged 84.43% in 2022 and soared 561.49% in 2023, its largest moves.
• Allogene Therapeutics' Shares Outstanding stood at $144.4 million in 2022, then advanced by 16.76% to $168.6 million in 2023, then increased by 25.83% to $212.2 million in 2024, then advanced by 8.11% to $229.4 million in 2025, then gained by 6.71% to $244.8 million in 2026.
• The last three Shares Outstanding figures came in at $244.8 million (Q1 2026), $229.4 million (Q4 2025), and $223.2 million (Q3 2025), per Business Quant data.